Under the Paperwork Reduction Act of 1 995, no persons are required to respond to a collection of information unles	
TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION	Docket Number (Optional) 02-1019-A1
In re Application of: Raeppel	
Application No.: 10/531,406	
Filed: April 14, 2005	
For: Inhibitors of Histone Deacetylase	
The owner MethylGene Inc. or 100 percent interest in the instance applied as provided below, the terminal part of the statutory term of any patent granted on the instant applied the expiration date of the full statutory term of any patent granted on pending reference Application Number on September 12, 2002, as such term is defined in 35 U.S.C. 154 and 173, and as the term of any application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending hereby agrees that any patent or the grant of any agreement or the reference application are commonly owned. This agreement runs with any patent granted	10/242,304 , filed patent granted on said reference reference application. The owner such period that it and any patent
binding upon the grantee, its successors or assigns.	**
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would exhed to the expiration date of the full statutory term as defined in 35 U.S. C. 154 and 173 of any patent granted ansal reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent or the pending reference application," in the event that any such patent granted on the pending reference application, application, and the pending reference application, application, and the pending reference application expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.	
Check either box 1 or 2 below, if appropriate.	
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
The undersigned is an attorney or agent of record. Reg. No. 37,142	
/Michael S. Greenfield/	December 28, 2006
Signature	Date
Michael S. Greenfield	
Typed or printed name	0.00.000
	312-913-0001 Telephone Number
Terminal disclaimer fee under 37 CFR 1.20(d) is included.	rooprono n a moo
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	

Form PTO/SB96 may be used for making this statement. See MPEP § 324.

This collection of information is required by 37 CFR 1.32 /L. the information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 1.22 and 37 CFR 1.11 and 1.14. This collection is estimated to use 12 mixtured to complete, including gathering-preparing, and submitting the completed application from the USPTO Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or applications for noticing this brutent, should be sent to the Cfile filtermation Officer, U.S. Patient and ADDRESS SEND TO: Commissioner for Patents, P.O. 180x 1450, MA 2013-1450, Do. NOT SEND TESS OF COMPLETED FORMS TO THIS

'Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).